"The discussion highlights concerns regarding potential dilution of current shareholders due to a proposed change in deal terms, where grant money is converted to equity. Additionally, there is skepticism about the long-term creditworthiness of the institution involved, particularly in light of the Trump administration's interest in reallocating Chips Act funds for an Intel stake."